Highlight
This multicentric, double-blind, phase III trial from India establishes that elagolix provides non-inferior pain relief compared to dienogest in women suffering from moderate-to-severe endometriosis-associated pain. Both treatments led to significant reductions in various pain domains, with comparable safety profiles and no adverse impact on bone mineral density over 24 weeks.
The study supports elagolix as an effective oral therapy alternative to dienogest, broadening options for personalized management of endometriosis pain.
